Newman Dignan & Sheerar Inc’s Oragenics OGEN Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$1.1K	–	201
2022 Q4	$1.1K	Hold	6	–	–	﹤0.01%	193
2022 Q3	$2	Buy	+6	New	+$3.5K	﹤0.01%	186
2022 Q2	–	Sell	-6	Closed	-$4	–	194
2022 Q1	$4	Hold	6	–	–	﹤0.01%	198
2021 Q4	$5K	Hold	6	–	–	﹤0.01%	205
2021 Q3	$7K	Buy	+6	New	+$7.24K	﹤0.01%	195

Other funds holding OGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

WWM

Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

Newman Dignan & Sheerar Inc's OGEN Position: Q1 2023 in Review

Newman Dignan & Sheerar Inc sold out of Oragenics (OGEN) in Q1 2023, closing a stake of 6 shares — an estimated $1.1K sold.

Newman Dignan & Sheerar Inc first reported a position in OGEN in Q3 2021 and held it in 5 quarters. The position peaked at $7K in Q3 2021. 10 funds tracked by Wall St. Rank hold OGEN as of Q1 2023.

Newman Dignan & Sheerar Inc reported no remaining Oragenics position as of Q1 2023 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 6 Oragenics shares in Q1 2023, an estimated $1.1K.
Newman Dignan & Sheerar Inc first reported a position in Oragenics in Q3 2021 and held it in 5 quarters.
Newman Dignan & Sheerar Inc's Oragenics position peaked at $7K in Q3 2021.
10 funds tracked by Wall St. Rank held Oragenics as of Q1 2023.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q1 2023, filed 28 Apr 2023.